Adocia starts Phase IIa human insulin trial
The company will evaluate around 20 patients with type 1 diabetes in the Phase IIa trial. The results from a Phase I trial demonstrated that the action of
Amgen has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Repatha (evolocumab) supporting its broader use prior to a first heart attack or stroke.